Eustace Mullins
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Nuremberg Revisited in Burma? an Assessment of the Potential Liability of Transnational Corporations and Their Officials in Burma Under International Criminal Law
NUREMBERG REVISITED IN BURMA? AN ASSESSMENT OF THE POTENTIAL LIABILITY OF TRANSNATIONAL CORPORATIONS AND THEIR OFFICIALS IN BURMA UNDER INTERNATIONAL CRIMINAL LAW By Mary Ann Johnson Navis A dissertation submitted to the Victoria University of Wellington in partial fulfilment of the requirements for the degree of Master of Laws Victoria University of Wellington 2010 1 ABSTRACT This dissertation focuses on the role played by officials of transnational corporations and transnational corporations themselves in the situation in Burma. The main aim of this dissertation is to assess the liability of officials of transnational corporations in Burma and transnational corporations in Burma for crimes against humanity such as slave labour and for war crimes such as plunder under International Criminal Law. However at present transnational corporations cannot be prosecuted under International Criminal Law as the International Criminal Court only has jurisdiction to try natural persons and not legal persons. In doing this analysis the theory of complicity, actus reus of aiding and abetting and the mens rea of aiding and abetting in relation to officials of transnational corporations will be explored and analysed to assess the liability of these officials in Burma. In doing this analysis the jurisprudence of inter alia the Nuremberg cases, the cases decided by the International Criminal Tribunal for the Former Yugoslavia (ICTY) and the International Criminal Tribunal for Rwanda (ICTR) will be used. This dissertation also examines the problems associated with suing or prosecuting transnational corporations due to the legal personality of transnational corporations and the structure of transnational corporations. At the end of the dissertation some recommendations are made so as to enable transnational corporations to be more transparent and accountable under the law. -
Beecham Group PLC and Another V Triomed (Pty) Ltd [2002] 4 All SA 193 (SCA)
Beecham Group PLC and another v Triomed (Pty) Ltd [2002] 4 All SA 193 (SCA) Division: Supreme Court of Appeal Date: 19 September 2002 Case No: 100/01 Before: Harms, Scott, Mpati, Conradie JJA and Jones AJA Sourced by: PR Cronje Summarised by: D.Harris Parallel Citation: 2003 (3) SA 639 (SCA) . Editor's Summary . Cases Referred to . Judgment . [1] Intellectual property Trade marks Registration of shape as trade mark Where shape is not intended to be used to distinguish owner's products from those of another, it cannot be regarded as a trade mark Application for expungement from trade marks register therefore allowed. Editor's Summary Both parties involved in the present matter were players in the pharmaceutical industry. The Appellants sought the upholding of a trade mark for the shape of a tablet, and a finding that the Respondent had infringed the trade mark. The Respondent imported a tablet with the same composition and shape as that of the Appellants. In the court a quo, the Respondent applied for the expungement from the trade mark register of the shape trade mark. The Appellants launched a counterapplication for relief for trade mark infringement. The latter application failed while that of the Respondent succeeded. Held Interested parties may apply to court for the removal of an entry wrongly made or remaining on the trade mark register. The first question posed by the Court was whether the Appellants' shape mark constituted a trade mark in terms of section 10(1) of the Trade Marks Act 194 of 1993 ("the Act"). -
Karl Heinz Roth Die Geschichte Der IG Farbenindustrie AG Von Der Gründung Bis Zum Ende
www.wollheim-memorial.de Karl Heinz Roth Die Geschichte der I.G. Farbenindustrie AG von der Gründung bis zum Ende der Weimarer Republik Einleitung . 1 Vom „Dreibund“ und „Dreierverband“ zur Interessengemeinschaft: Entwicklungslinien bis zum Ende des Ersten Weltkriegs . 1 Der Weg zurück zum Weltkonzern: Die Interessengemeinschaft in der Weimarer Republik . 9 Kehrtwende in der Weltwirtschaftskrise (1929/30–1932/33) . 16 Norbert Wollheim Memorial J.W. Goethe-Universität / Fritz Bauer Institut Frankfurt am Main 2009 www.wollheim-memorial.de Karl Heinz Roth: I.G. Farben bis zum Ende der Weimarer Republik, S. 1 Einleitung Zusammen mit seinen Vorläufern hat der I.G. Farben-Konzern die Geschichte der ersten Hälfte des 20. Jahrhunderts in exponierter Stellung mitgeprägt. Er be- herrschte die Chemieindustrie Mitteleuropas und kontrollierte große Teile des Weltmarkts für Farben, Arzneimittel und Zwischenprodukte. Mit seinen technolo- gischen Innovationen gehörte er zu den Begründern des Chemiezeitalters, das die gesamte Wirtschaftsstruktur veränderte. Auch die wirtschaftspolitischen Rahmenbedingungen gerieten zunehmend unter den Einfluss seiner leitenden Manager. Im Ersten Weltkrieg wurden sie zu Mitgestaltern einer aggressiven „Staatskonjunktur“, hinter der sich die Abgründe des Chemiewaffeneinsatzes, der Kriegsausweitung durch synthetische Sprengstoffe, der Ausnutzung der Annexi- onspolitik und der Ausbeutung von Zwangsarbeitern auftaten. Nach dem Kriegs- ende behinderten die dabei entstandenen Überkapazitäten die Rückkehr zur Frie- denswirtschaft -
Explaining Corporate Success Abstract
Explaining corporate success: Britain’s best performing firms, 1949-1985 D.M. Higgins, S. Toms The York Management School Abstract The paper synthesises theories of competitive advantage in a dynamic framework to explain the determinants of corporate success. A model is presented linking the firm’s resource audit and dynamic capabilities with the rate of market growth. For the purposes of testing the model, an examination of the performance of all British quoted companies during the period is conducted with reference to achieved long run average rates of return on capital employed. The best performing firms are analysed in more detail and their strategies mapped according to the model criteria. Conclusions are then drawn on the possible strategies for achieving long run corporate success in terms of above average financial returns. Correspondence Steven Toms Joint Editor: Business History Professor of Accounting and Finance and Head of School The York Management School Sally Baldwin Buildings University of York York YO10 5DD Tel: (44) 1904-434122 Fax: (44) 1904-433 431 Email: [email protected] http://www.york.ac.uk/management/staff/StaffProfiles/SToms.htm 1 Explaining corporate success: Britain’s best performing firms, 1949-1985 1. Introduction Competitive advantage and more specifically sustained competitive advantage and its determinants, has become an important research topic in the business and management and industrial organisation literatures. Sustained competitive advantage (SCA) implies not just achieving superior returns, but achieving them over a protracted period of time. It is therefore surprising that the overwhelming majority of this literature has not explored the notion of sustained competitive advantage from a historical perspective. -
Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000
GlaxoSmithKline 01 GlaxoSmithKline plc Annual Report for the year ended 31st December 2000 Contents Report of the Directors 02 Financial summary 03 Joint statement by the Chairman and the Chief Executive Officer 05 Description of business 29 Corporate governance 37 Remuneration report 47 Operating and financial review and prospects 69 Financial statements 70 Directors’ statements of responsibility 71 Report by the auditors 72 Consolidated statement of profit and loss 72 Consolidated statement of total recognised gains and losses 74 Consolidated statement of cash flow 76 Consolidated balance sheet 76 Reconciliation of movements in equity shareholders’ funds 77 Company balance sheet 78 Notes to the financial statements 136 Group companies 142 Principal financial statements in US$ 144 Financial record 153 Investor information 154 Shareholder return 156 Taxation information for shareholders 157 Shareholder information 158 Share capital 160 Cross reference to Form 20-F 162 Glossary of terms The Annual Report was approved by the Board 163 Index of Directors on 22nd March 2001 and published on 12th April 2001. Contact details 02 GlaxoSmithKline Financial summary 2000 1999 Increase Business performance £m £m CER % £ % Sales 18,079 16,164 9 12 Trading profit 5,026 4,378 12 15 Profit before taxation 5,327 4,708 11 13 Earnings/Net income 3,697 3,222 13 15 Earnings per Ordinary Share 61.0p 52.7p 14 16 Total results Profit before taxation 6,029 4,236 Earnings/Net income 4,154 2,859 Earnings per Ordinary Share 68.5p 46.7p Business performance: results exclude merger items and restructuring costs; 1999 sales and trading profit exclude the Healthcare Services businesses which were disposed of in 1999. -
JANUARY 2017 | VOLUME 102 NUMBER 1 | AMERICAN COLLEGE of SURGEONS Bulletin Contents
JANUARY 2017 | VOLUME 102 NUMBER 1 | AMERICAN COLLEGE OF SURGEONS Bulletin Contents FEATURES COVER STORY: Reimbursement changes in 2017 The 2017 Medicare physician fee schedule: An overview of provisions that will affect surgical practice 11 Lauren Foe, MPH; Jan Nagle, MS, RPh; and Vinita Ollapally, JD 2017 CPT coding changes 16 Albert Bothe, MD, FACS; Megan McNally, MD, FACS; and Jan Nagle, MS, RPh Profiles in surgical research: Mary T. Hawn, MD, MPH, FACS 26 Juliet A. Emamaullee, MD, PhD, FRCSC, and Kamal M. F. Itani, MD, FACS The 2016 RAS-ACS annual Communications Committee essay contest: An introduction 33 Erin Garvey, MD | 1 First-place essay: Paying it forward: When the mentee becomes the mentor 34 Kevin Koo, MD, MPH, MPhil Highlights of Clinical Congress 2016 35 ACS Officers, Regents, and Board of Governors’ Executive Committee 46 JAN 2017 BULLETIN American College of Surgeons Contents continued COLUMNS A look at The Joint Commission: ASCPA-SurgeonsPAC makes an Annual report provides details impact on 2016 congressional Looking forward 8 on patient safety, quality elections 80 David B. Hoyt, MD, FACS improvements 69 Katie Oehmen ACS NSQIP Best Practices case Carlos A. Pellegrini, MD, Call for nominations for the ACS studies: Impact of SSI reduction FACS, FRCSI(Hon), FRCS(Hon), Board of Regents and ACS strategy after colorectal resection 49 FRCSEd(Hon) Officers-Elect 82 Lisa A. Wilbert, RN NTDB data points: Annual Report Nominations for 2017 Dispatches from rural surgeons: 2016: Almost a 10 71 volunteerism and humanitarian Rural surgery: High pressure Richard J. Fantus, MD, FACS awards due February 28 84 but rewarding 55 Report on ACSPA/ACS activities, Susan Long, MD, FACS NEWS October 2016 86 From residency to retirement: In memoriam: Jay L. -
I.G. Farben's Petro-Chemical Plant and Concentration Camp at Auschwitz Robert Simon Yavner Old Dominion University
Old Dominion University ODU Digital Commons History Theses & Dissertations History Summer 1984 I.G. Farben's Petro-Chemical Plant and Concentration Camp at Auschwitz Robert Simon Yavner Old Dominion University Follow this and additional works at: https://digitalcommons.odu.edu/history_etds Part of the Economic History Commons, and the European History Commons Recommended Citation Yavner, Robert S.. "I.G. Farben's Petro-Chemical Plant and Concentration Camp at Auschwitz" (1984). Master of Arts (MA), thesis, History, Old Dominion University, DOI: 10.25777/7cqx-5d23 https://digitalcommons.odu.edu/history_etds/27 This Thesis is brought to you for free and open access by the History at ODU Digital Commons. It has been accepted for inclusion in History Theses & Dissertations by an authorized administrator of ODU Digital Commons. For more information, please contact [email protected]. 1.6. FARBEN'S PETRO-CHEMICAL PLANT AND CONCENTRATION CAMP AT AUSCHWITZ by Robert Simon Yavner B.A. May 1976, Gardner-Webb College A Thesis Submitted to the Faculty of Old Dominion University in Partial Fulfillment of the Requirements for the Degree of MASTER OF ARTS HISTORY OLD DOMINION UNIVERSITY August 1984 Approved by: )arw±n Bostick (Director) Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. Copyright by Robert Simon Yavner 1984 All Rights Reserved Reproduced with permission of the copyright owner. Further reproduction prohibited without permission. ABSTRACT I.G. FARBEN’S PETRO-CHEMICAL PLANT AND CONCENTRATION CAMP AT AUSCHWITZ Robert Simon Yavner Old Dominion University, 1984 Director: Dr. Darwin Bostick This study examines the history of the petro chemical plant and concentration camp run by I.G. -
Upper West Side / Central Park
Upper West Side / Central Park Streets West 87 Street, K4-8 West 107 Street, A3-8 Beresford Apartments, The, M8 Summit Rock, M9 Contemporary African Art Gallery, A3 Greystone Hotel, H5 JHS 54, A7 Nicholas Roerich Museum, A3 Riverside Montessori School, G3 St. Ignatius Episcopal Church, K4 Symphony Space, G4 Subway Stations Amsterdam Avenue, A-M5 West 88 Street, J4-8 West 108 Street, A3-8 Bloomingdale Playground, B6 Tennis Courts, F10 Days Hotel, G5 Grosvenor Neighborhood House Kateri Residence, K2 Normandy Apartments, K2 Riverside Park, A2-M2 St. Mary Magdalen Orth. Church, A7 Thalia Theater, F4 81 St-Musuem of Natural History Key Broadway, A4, E-M5 West 89 Street, J4-8 West Drive, B10, F9, M9 Bloomingdale Public Library, D6 The Loch, C11 De La Salle Academy, F5 YMCA, B6 La Perla Community Garden, B7 Open Door Child Care Center, D7 Beach Volleyball Courts, B2 St. Matthew & St. Timothy Trinity Lutheran Church, D6 BC, M9 accessible Central Park West, A-M8 West 90 Street (Henry J. West End Avenue, A-M4 Brandon Residence for Women, L3 The Pool, C9 Douglass Houses, C6, C7 Harcourt Residence Hotel, F4 Louis Brandeis High School, L6 Park West Montessori School, C8 Crabapple Grove Garden, G2 Episcopal Church, L7 Trinity School, H6 86 St 1, K5 entrance & exit Columbus Avenue, A-M7 Browne Blvd), J4-8 Bretton Hall, L5 Central Park Hostel, C8 Dwight School, J8 Head Start, A6, C4, C7, F7, H7, K6 Malibu Studios Hotel, C5 Park West Village, E6, E7 Dinosaur Playground, E2 St. Matthew’s & St. Timothy’s Ukrainian Orthodox Church, M6 86 St , K9 Subway station and BC exits Duke Ellington Blvd West 91 Street, H4-8 Points of Interest Brewster Hotel, K8 Chabad Lubavitch of the West Side, G6 Edward A. -
Government Gazette Republic of Namibia
GOVERNMENT GAZETTE OF THE REPUBLIC OF NAMIBIA N$16.68 WINDHOEK- 2 September 1996 No. 1396 CONTENTS TRADE MARKS .............................................................................................................................. APPLICATIONS FOR REGISTRATION OF TRADE MARKS IN NAMIBIA (Applications accepted in terms of Act No. 48 of 1973) '\ Any person who has grounds for objection to any of the following trade marks, may, within the prescribed time, lodge Notice of Opposition on form SM6 con tained in the Second Schedule to the Trade Marks Rules in Namibia, 1973. The prescribed time is two months after the date of advertisement. This period may on application be extended by the Registrar. Where the Gazette is issued late, the period of opposition will count as from the date of issue and a notice relating thereto will be displayed on the public notice board in the Trade Marks Registry. Formal opposition should not be lodged until after notice has been given by letter to the applicant for registration so as to afford him an opportunity of withdrawing his application before the expense of preparing the Notice of Opposition is in curred. Failing such notice to the applicant an opponent may not succeed in ob taining an order for costs. "B" preceding the number indicates Part B of the Trade Mark Register. Neither the office mentioned hereunder nor Central Bureau Services (Pty) Ltd., acting on behalf of the Government of Namibia, guarantee the accuracy of this publication or undertake any responsibility for errors or omissions or their conse quences. E.T. KAMBOUA REGISTRAR OF TRADE MARKS FOR NAMIBIA 2 Government Gazette 2 September 1996 No. 1396 TRADE MARKS REMOVED FROM 1 JULY 1992 TO 30 JUNE 1996 NO. -
A Thesis Entitled an Oral Dosage Form of Ceftriaxone Sodium Using Enteric
A Thesis entitled An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy Option _________________________________________ Jerry Nesamony, Ph.D., Committee Chair _________________________________________ Sai Hanuman Sagar Boddu, Ph.D, Committee Member _________________________________________ Youssef Sari, Ph.D., Committee Member _________________________________________ Patricia R. Komuniecki, PhD, Dean College of Graduate Studies The University of Toledo May 2015 Copyright 2015, Darshan Narendra Lalwani This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy option The University of Toledo May 2015 Purpose: Ceftriaxone (CTZ) is a broad spectrum semisynthetic, third generation cephalosporin antibiotic. It is an acid labile drug belonging to class III of biopharmaceutical classification system (BCS). It can be solvated quickly but suffers from the drawback of poor oral bioavailability owing to its limited permeability through -
TOWERS NURSING HOME, 2 West 106Th Street
.. - Landmarks Preservation Colmlission August 17, 1976, Number I LP-0938 TOWERS NURSING HOME, 2 West 106th Street. 32 West 106th Street and 455 Central Park West. Borough of Manhattan. Original building, 1884-86; additions. 1889-90. and 1925-26; outbui !ding, 1886-87; architect Charles Coolidge Haight. Landmark Site: Borough of Manhattan Tax Map Block 1841, Lot 25. On July 13, 1976, the Landmarks Preservation Commission held a public · hearing on the proposed designation as a Landmark of the Towers Nursing Home and the proposed designation of the related Landmark Site (Item No. 9). The hearing had been duly advertised in accordance with the provisions of law. Twenty-one witnesses spoke in favor of designation. There were two speakers in opposition to designation. The Commission has also received many letters and other expressions of support in favor of designation. A number of letters have been received in opposition to designation. DESCRIPTION AND ANALYSIS The Towers Nursing Home, originally the New York Cancer Hospital, was built in three sections between 1884 and 1890 from plans by the noted New York City architect Charles Coolidge Haight. Prominently located at the wide · intersection of Centra·l Park West and West 106th Street, the Towers is a toea I point for the surrounding neighborhood, and with its towers crowned by conical roofs, is one of the most distinguished buildings facing Central Park. The New York Cancer Hospital was founded in 1884 to further the study and treatment of cancer. In 1882 John Jacob Astor had made an offer to the Woman's Hospital to fund a pavilion for the treatment of cancer patients. -
281165000 Dormitory Authority of the State Of
NEW ISSUE Moody’s: “Aa2” Standard & Poor’s: “AA” FitchRatings: “AA” (See “Ratings” herein) $281,165,000 DORMITORY AUTHORITY OF THE STATE OF NEW YORK MEMORIAL SLOAN-KETTERING CANCER CENTER REVENUE BONDS, SERIES 2008A2 Dated: Date of Delivery Due: July 1, as shown on inside cover Payment and Security: The Memorial Sloan-Kettering Cancer Center Revenue Bonds, Series 2008A2 Bonds (the “Series 2008A2 Bonds”) are special obligations of the Dormitory Authority of the State of New York (the “Authority”) payable from and secured by a pledge of (i) certain payments to be made under the Loan Agreement (the “2002 Loan Agreement”), dated as of December 5, 2001, as amended, between Memorial Sloan-Kettering Cancer Center (the “Center”) and the Authority and Guaranties (the “Guaranties”), dated as of December 5, 2001, from the Sloan-Kettering Institute for Cancer Research and S.K.I. Realty, Inc. to the Authority (the “Revenues”) and (ii) all funds and accounts (excluding the Arbitrage Rebate Fund and any fund established for the payment of the Purchase Price of Option Bonds tendered for purchase) established under the Authority’s Memorial Sloan-Kettering Cancer Center Revenue Bond Resolution adopted December 5, 2001 and the Series 2008A Resolution adopted March 26, 2008 (collectively, the “Resolution”). The 2002 Loan Agreement is a general, unsecured obligation of the Center and requires the Center to pay, in addition to the fees and expenses of the Authority and the Trustee, amounts sufficient to pay the principal and Redemption Price of and interest on all Bonds issued under the Resolution, including the Series 2008A2 Bonds, as such payments become due.